Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC

Introduction: Blood-based next-generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect tumor-associated mutations in patients with SCLC. We sought to characterize the relationship between ctDNA mean variant allele frequency (VAF) and radiographic total-body tumor vol...

Full description

Bibliographic Details
Main Authors: Jarrod T. Smith, BA, Aneri Balar, MD, Dhairya A. Lakhani, MD, Christien Kluwe, MD, PhD, Zhiguo Zhao, MS, Prasad Kopparapu, PhD, Karinna Almodovar, PhD, Anel Muterspaugh, MPH, CPH, Yingjun Yan, MS, Sally York, MD, PhD, Leora Horn, MD, MSc, Sanja Antic, MS, Caterina Bertucci, MPA, Tristan Shaffer, MS, Lauren Hodsdon, MPH, Kavita Garg, PhD, Seyed Ali Hosseini, MD, PhD, Lee Lim, PhD, Evan Osmundson, MD, PhD, Pierre P. Massion, MD, Christine M. Lovly, MD, PhD, Wade Iams, MD
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:JTO Clinical and Research Reports
Subjects:
Circulating tumor DNA (ctDNA)
Small cell lung cancer (SCLC)
Variant allele frequency (VAF)
Total-body tumor volume (TV)
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301569

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301569

Similar Items